CFTR and cystic fibrosis: Furthermore, using the CRISPR-Cas9 genome editing system, Schwank et al. were able to correct the deletion at position 508 of cystic fibrosis transmembrane conductor receptor (CFTR) with homologous recombination on intestinal organoid from patients with CF, providing a potential application of the engineered organoid for gene therapies and transplantation approaches [15].